A study of placental umbilical cord whole blood transfusion in 72 patients with anemia and emaciation in the background of cancer

In the under-resourced world, transfusion to advanced oncological patients involves two major problems, i.e., (a) transfusion transmitted disease, and (b) infrastructural deficiency. Many hospitals cannot cope with the specialized requirements of immunocompromised cancer victims, for instance, leucoreduction, selective apheresis, irradiation of the blood, viral inactivation of the blood by solvent and/or detergent treatment or photochemical inactivation using psoralen or long wavelength ultraviolet light and cytomegalovirus safe blood. The exorbitant cost of red blood cell (RBC) substitutes like hemoglobin-based oxygen carriers or perflurocarbon emulsions, liposome encapsulated hemoglobin, is simply unacceptable for an average oncological patient in the developing world. Moreover, it should be underscored that none of the total blood functions are replaced by any available so-called blood substitute, the primary function of which is oxygen delivery and volume expansion only. A more accurate term should be red cell substitute. Cord blood, because of its rich mix of fetal and adult hemoglobin, platelet and white blood cell (WBC) count, and plasma filled with cytokine and growth factors--as well as its hypoantigenic nature and altered metabolic profile--has all the potential of a real and safe alternative to adult blood during emergencies or any etiology of blood loss. In the present series, the collection of cord blood varied from 54 ml-128 ml, mean 82 ml +/- 7.6 ml SD; mean packed cell volume 48 +/- 4.1% SD; mean percent hemoglobin concentration 16.4 g/dl +/- 1.6 g/dl SD. Not a single case of immunological or non immunological reaction has been encountered so far after transfusion of cord blood to cancer patients with percent of hemoglobin 8 g/dl or less. It appears that the medical fraternity can safely use this precious gift of nature-- which is free from infection, hypoantigenic with altered metabolic profile, filled with growth factors and cytokine-filled plasma, and has the potential of a higher oxygen carrying capacity than adult blood--as an emergency source of blood for the management of advanced cancer cases with anemia.

Placental cord whole; Safe blood transfusion; Advanced cancer with anemia

[1] Smith R.E. Jr., Tchekmedyian S.: "Practitioners'practical model for managing cancer related anemia". Oncology, 2002, 16 (9 suppl. 10), 55.

[2] Pirker R., Wiesenberger K., Pohl G., Minar W.: "Anemia in lung cancer: clinical impact and management". Clin. Lung Cancer, 2003, 5, 90.

[3] Tchekmedyian N.S.: "Anemia in cancer patients: significance, ep1- demiology, and current therapy". Oncology, 2002, 16, (9 suppl. 10), 17.

[4] Steensma D.P.: "Management of anemia in patients with cancer". Curr. Oncol. Rep., 2004, 6, 297.

[5] Kolesar J.M.: "Novel approaches to anemia associated with cancer and chemotherapy". Am. J. Health Syst. Pharm., 2002, 59 (15 suppl. 4), S8.

[6] Harrison L.B., Shasha D., Home! P.: "Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment". Oncology, 2002, 63 (suppl. 2), 11.

[7] Ludwig H., Fritz E.: "Anemia of cancer patients: patient selection and patient stratification for epoetin treatment". Semin. Oncol., 1998, 25 (3 suppl. 7), 35.

[8] Tscherning-Casper C., Papadogiannakis N., Anvret M., Stolpe L., Lindgren S., Bohlin A.B. et al.: "The trophoblastic epithelial barrier is not infected in full-term placentae of human immunodeficiency virus-seropositive mothers undergoing antiretroviral therapy". J. Virol., 1999, 73, 9673.

[9] Gluckman E., Broxmeyer H.E., Auerback A.D., Friedman H.S., Douglas G.W. et al.: "Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from al) HLA identical sibling". N. Engl. J. Med., 1989, 32, 1174-8.

[10] Broxmeyer H.E., Hangoc G., Cooper S., Riberio R., Graves V. et al.: "Growth characteristics and expansion of human umbilical cord blood and estimation of its potential for transplantation in adults". Proc. Natl. Acad. Sci, 1992, 89, 4109.

[11] Helen P.: "Artificial blood". http://www.nature.com/nsu/980702/980702-5html.

[12] Hoag H.: "Blood substitute from worm show promise-hemoglobm from sea creature could replace red cells". 4" June 2003, http://www.nature.com/nsu/030602/030602-7html.

[13] Bhattacharya N., Mukherjee K.L., Chettri M.K., Banerjee T., Mam U., Bhattacharya S.: "A study report of 174 of units of placental umbilical cord whole blood transfusion in 62 patients as a rich source of fetal hemoglobin supply in different indications of blood transfusion". Clin. Exp. Obstet. Gynecol., 2001, 28, 47.

[14] Bhattacharya N.: "Placental umbilical cord whole blood transfusion: a safe and genuine blood substitute for patients of the underresourced world at emergency". J. Am. Coll. Surg., 2005, 200/4, 557.

[15] Usher R., Shephard M., Lind J.: "The blood volume of the newborn infants and the placental transfer". Acta Pediatr., 1963, 52, 497.

[16] Haselhorst G., Allmeling A.: "Die gewichtszunahme von neugeborenen infolge postnataler transfusion". Z. Geburtshilfe Perinatol., 1930, 98, 103.

[17] Oski F.A., Naiman J.L.: "Hematologic Problems in the Newborn". 3''edition, Philadelphia, WB Saunders, 1992.

[18] Karaklis A., Fessas P.: "The normal minor components of fetal hemoglobin". Acta Haemaol., 1963, 29, 267.

[19] Davis J.A., Dobbing J.: "Scientific Foundation of Pediatrics". London, William Heineman Med. Books, 1981, 514.

[20] Killmartin J.V.: "Interaction of hemoglobin with protein, CO & 2-3 diphosphoglycerate". Br. Med. Bull., 1976, 32, 209.

[21] Delivoria Padopoulos M., Roncevic N.P., Oski F.A.: "Post natal changes in the oxygen transfer of term premature and sick infants: The role of 2-3 diphosphoglycerate and the adult hemoglobin" Pediatr. Res., 1971, 5, 235.

[22] Fakuda M.N., Levery S.B.: "Glycolipids of fetal newborn and adult erythrocytes". Biochemistry, 1983, 22, 5034.

[23] Marsh W.L.: " Erythrocyte blood group in humans". In: D.G. Nathan, F.A. Oski(eds.), Hematology of Infancy and Childhood, philadelphia,W.B. Saunders, 1987.

[24] Vulpis N.: "Studies on the antigens of the human red cell ghosts" Acta Haematol., 1963, 30,229.

[25] Schroeder M.L., Rayner H.L.: "Transfusion of blood and blood components". In: Bithell T.C.,F oerster J., Athens J.W.,L ukes J.N (eds.), Wintrobes' Clinical Hematology, 9''edition, Philadelphia Lea and Febiger, 1993, 675.

[26] Corash L.: "Inactivation of viruses, bacteria protozoa and leucocytes in platelet concentrates: current research perspective". Trans. Med. Rev., 13, 18.

[27] Dobroszycki J., Herwaldt B.L., Boctor F. et al.: "A cluster of transfusion associated Babesiosis cases traced to a single asymptomatic donor". JAMA, 1999, 281, 927.

[28] Moore E.E.: " Blood substitute the future is now". J. Am. Coll Surg., 2003, 196, 1.

[29] Sloan E.P., Koenigsberg M., Gens D. et al.: "Diasprin cross linked hemoglobin (DCLHb) in the treatment of severe hemorrhagic shock: a randomized controlled efficacy trial". JAMA, 1999, 282, 1857.

[30] Klein H.G.: "The prospect of red cell substitute". NEJM, 2000, 342, 1666.

[31] Goodnough L.T. et al.: " Blood Transfusion". First of two parts, N. Engl. J. Med., 1999, 340, 438.

[32] Mortimer P.: "Making blood safer". Br. Med. J., 2002, 325, 400.

[33] Goodnough L.T.: "Transfusion Medicine-blood Conservation. Second of Two Parts". N. Engl. J. Med., 1999, 340, 525.

[34] Guideline for the gamma irradiation of the blood components for the prevention of the transfusion associated graft vs host disease. BCSH blood transfusion task force". Transjus. Med., 1996, 6, 261.

[35] Tom C.: "Newborns might help malaria kids - blood from umbilical cords could treat anemia caused by tropical disease". 2002, 15, http://www.nature.com/nsu/021 ll l/021111-l lhtml.

[36] Hassal 0., Bedu-Addo G., Adarkwa M., Danso K., Bates I.: “Umb山cal cord blood for transfusion in children with sever anemia in under-resourced countries". Lancet, 2003, 361, 678.

[37] World Health Organization, International Federation of Red Cross and Red Crescent Societies: "Safe blood starts with me". Geneva, World Health Organization, 2000, 12.

[38] Sloand E.M., Pitt E., Klein H.G.: "Safety of blood supply". JAMA, 1995, 274, 1368.

[39] Amberson W.R.,M ulder A.G.,S teggerda F.R. et al.: "Mammalian life without red blood corpuscles". Science, 1933, 78, 106.

[40] Bhattacharya N.: "Placental umbilical cord whole blood transfusion" (letter). J. Am. Coll. Surg., 2004, 199/2, 347.

[41] Bhattacharya N., Bandopadhyay T., Bhattacharya M., Bhattacharya S.: "Do not discard 99.99% of the human placental

umbitical cord blood for the sake of stem cells only". http://bmj.com/cgi/eletters/323/7304/60# 1687 4, Oct. 5, 2001.

[42] Bhattacharya N., Bandyopadhyay T., Bhattacharya M., Bhattacharya S.: "Immunization and fetal cell/tissue transplant: a new strategy for geriatric treatment". http://bmj.com/cgi/eletters/ 323/7320/1025/b#21055, Apr. 5, 2002.

[43] Bhattacharya N. et al.: "Umbilical cord whole blood transfusion: a suggested strategy to combat blood scarcity in Ireland". http://bmj.com/cgi/eletters/324/73301/134/c# 19096, Jan. 27, 2002.

[44] Bhattacharya N. et al.: "The safe use of placental umbilical cord whole blood transfusion in patients suffering with anemia and Thalassemia in under-resourced regions of the world" http://bmj.com/cgi/eletters/321/7269/l 117#62372, Jun. 9, 2004.

[45] Bhattacharya N. et al.: "Umbilical cord whole blood transfusion in HIV patients with anemia and emaciation". http://bmj.com/cgi/eletters/327 /7414/562-a#59738, May 17, 2004.

[46] Bhattacharya N. et al.: "Utilization of a genuine blood substitute: a suggestion to the medical fraternity in Iraqi Hospital" http://bmj.com/cgi/eletters/326/7391/675#30850, March 30, 2003.

[47] Bhattacharya N. et al.: "A preliminary study report on placentalumbilical cord blood transfusion in victims of anemia with leprosy in under-resourced regions of the world". http://bmj.com/cgi/eletters/328/7454/l 44 7 /=63828, June 22, 2004.

[48] Bhattacharya N., Chhetri M.K., Mukherjee K.L., Ghosh A.B., Samanta B.K., Mitra R. et al.: "Can human fetal cortical brain tissue transplant (upto 20 weeks) sustain its metabolic and oxygen requirements in a heterotrophic site outside brain? A study of 12 volunteers with Parkinson's disease". Clin. Exp. Obstet. Gynaecol., 2002, 29, 4.

[49] Bhattacharya N., Chhetri M.K., Mukherjee K.L., Das S.P., Mukherjee A., Bhattacharya M., Bhattacharya S.: "Human fetal adnenal transplant: a possible role in relieving intractable pain in advanced rheumatoid arthritis". Clin. Exp. Obstet. Gynecol., 2002, 29, 3.

[50] Bhattacharya N., Mukherjee K.L., Chettri M.K., Banerjee T., Bhattacharya S., Ghosh A.B., Battacharya M.: "A unique experience with human pre-immune (12 weeks) and hypoimmune (16 weeks) fetal thymus transplant in a vascular subcutaneous axillary fold in patients with advanced cancer: a report of two cases". Eur. J. Gynecol. Oneal., 2001, 22, 4.

[51] Bhattacharya N.: "Fetal tissue/organ transplant in HLA randomized adult's vascular subcutaneous axillary fold: a preliminary report of 14 patients". Clin; Exp. Obstet. Gynecol., 2001, 28, 233.

[52] Bhattacharya N.: "Fetal cell/tissue therapy in adult disease: a new horizon in regenerative medicine". Clin. Exp. Obstet. Gynecol., 2004, 31, 167.